RayKnowChina Research Map
Shortlist

ZhuhaiSun Yat-sen University

Fifth Affiliated Hospital of Sun Yat-sen University

中山大学附属第五医院

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Fifth Affiliated Hospital of Sun Yat-sen University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌14 papers led8 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led
  3. Hepatocellular carcinoma肝细胞癌43 papers led1 open trial led
  4. Retinoblastoma视网膜母细胞瘤1 paper led
  5. Chordoma脊索瘤1 paper led
  6. Osteosarcoma骨肉瘤1 paper led
  7. Neuroblastoma神经母细胞瘤0 papers led
  8. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
  9. Beta thalassaemiaβ 地中海贫血0 papers led
  10. Hepatic echinococcosis肝包虫病1 paper led
  11. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  12. IgA nephropathyIgA 肾病2 papers led

Not listed for: Stomach cancer, Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 14 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
14
2021–2025
Trials led
13
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 4420242025: 442025

2 hospitals in Zhuhai for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06870435

    Age 30 years to 69 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  2. Recruiting
    Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07188584

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  3. Recruiting
    Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07581821

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  4. Recruiting
    Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06472713

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  5. Recruiting
    Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06533267

    Age 18 years to 75 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  6. Recruiting
    Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06675214

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  7. Recruiting
    "Xijiang Project" Screening Cohort for NPC
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06787456

    Age 30 years to 69 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  8. Recruiting
    Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT06529562

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  9. Recruiting
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07070479

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai

  10. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  11. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  12. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  13. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  14. Recruiting
    Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06688760

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  15. Recruiting
    Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2020-06
    Registry
    NCT04425265

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  16. Recruiting
    Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-07
    Registry
    NCT04453813

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  17. Recruiting
    Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-09
    Registry
    NCT04453826

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryNasopharyngeal carcinoma dept.Medical oncologyPathology / laboratory medicine
Papers it led14
  1. Clinical and Genomic Phenotype of Brain Metastasis in Nasopharyngeal Carcinoma.2025Molecular carcinogenesis
  2. Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma.2025Nature genetics
  3. Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. Nasopharyngeal Endoscopic Submucosal Dissection (NESD) for Stage I Nasopharyngeal Carcinoma.2025The Laryngoscope
  5. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.2024Cancer immunology, immunotherapy : CIIFree full text
  6. Diffusion-weighted MRI at the Late Stage after Radiotherapy for Evaluating Salivary Gland Injury.2024Current medical imaging
  7. EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma.2024Journal of translational medicineFree full text
  8. The Relationship Between the hOGG1 rs1052133 Polymorphism and the Occurrence of Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.2024Technology in cancer research & treatmentFree full text
  9. The valuable role of dynamic 18F FDG PET/CT-derived kinetic parameter Ki in patients with nasopharyngeal carcinoma prior to radiotherapy: A prospective study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  10. Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin.2022MedicineFree full text
  11. Long non-coding RNA SPRY4-IT1 promotes proliferation and metastasis in nasopharyngeal carcinoma cell.2022PeerJFree full text
  12. RNAi-mediated knockdown of PFK1 decreases the invasive capability and metastasis of nasopharyngeal carcinoma cell line, CNE-2.2021Cell cycle (Georgetown, Tex.)Free full text
  13. The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.2021Drug design, development and therapyFree full text
  14. Pathological and genomic phenotype of second neuroendocrine carcinoma during long-term follow-up after radical radiotherapy for nasopharyngeal carcinoma.2021Radiation oncology (London, England)Free full text
All its trials on ClinicalTrials.gov, any status27
  1. Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue ImagingStatus unknownNCT06129201Lead sponsorStart 2023-11
  2. Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal CarcinomaWithdrawnNCT05290194Lead sponsorPhase 2Start 2022-03
  3. Prognostic Prediction of NPC Based on MR Diffusion-weighted ImagingStatus unknownNCT05112510Lead sponsorStart 2021-06
  4. Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04522050Lead sponsorPhase 1Start 2018-10
  5. Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical TrialCompletedNCT03188497Lead sponsorPhase 1Start 2016-06
  6. Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal CancerRecruitingNCT07188584Lead (inferred)Phase 3Start 2025-08
  7. Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk AreasRecruitingNCT06870435Lead (inferred)N/AStart 2025-01
  8. Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingNCT07581821Lead (inferred)Phase 2Start 2025-09
  9. Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.RecruitingNCT06533267Lead (inferred)N/AStart 2024-03
  10. "Xijiang Project" Screening Cohort for NPCRecruitingNCT06787456Lead (inferred)Start 2024-11
  11. Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPCRecruitingNCT06472713Lead (inferred)Phase 2Start 2024-07
  12. Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.RecruitingNCT06675214Lead (inferred)Phase 3Start 2024-07
  13. Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.RecruitingNCT06529562Lead (inferred)N/AStart 2022-11
  14. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  15. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  16. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Study sitePhase 2Start 2025-06
  17. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  18. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  19. Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal CarcinomaRecruitingNCT06688760Study siteN/AStart 2023-11
  20. Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT04453826Study sitePhase 3Start 2020-09
  21. Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaRecruitingNCT04453813Study sitePhase 3Start 2020-07
  22. Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal CarcinomaRecruitingNCT04425265Study siteN/AStart 2020-06
  23. To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal CancerStatus unknownNCT05198531Study sitePhase 1/Phase 2Start 2022-01
  24. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedNCT05563480Study sitePhase 2Start 2022-10
  25. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  26. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
  27. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
More papers found outside PubMed (not counted)22
  1. 1377P TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial2025Annals of Oncologyarticle
  2. A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  3. ASO Visual Abstract: Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma2025Annals of Surgical Oncologyarticle
  4. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  5. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncologyconference-abstract
  6. Database for high-risk nasopharyngeal carcinoma treated with chemoradiotherapy and immunotherapy2025DRYADdataset
  7. Establishment and development of minimally invasive surgery for nasopharyngeal carcinoma2025Clinical Surgical Oncologyarticle
  8. Post‑irradiation mastoid mucosa disease in patients with nasopharyngeal carcinoma after radiotherapy: A large‑cohort and long‑term study2025Oncology Lettersarticle
  9. 153P Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study2024Immuno-Oncology Technologyarticle
  10. 892P Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma2024Annals of Oncologyarticle
  11. A prospective multicenter trial of dose escalation for weekly gemcitabine concurrent with intensity-modulated radiotherapy following cisplatin and gemcitabine induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma2024Journal of Clinical Oncologyconference-abstract
  12. Radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma: Updated results from a multicenter, open-label, non-inferiority, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  13. The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.2024Journal of Clinical Oncologyconference-abstract
  14. A new discovery of folic acid derivatives to improve the efficacy of PF regimen in the treatment of nasopharyngeal carcinoma2023Research Squarepreprint
  15. Adverse prognosis of nasopharyngeal carcinoma following long-term exposure to multiple air pollutants2023Environmental Chemistry Lettersarticle
  16. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023Venue not listedother
  17. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023Venue not listedother
  18. Exploring the current problem of target delineation based on the characteristics of axillary lymph node metastasis in nasopharyngeal carcinoma2023Research Squarepreprint
  19. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2023Research Squarepreprint
  20. The relationship between the hOGG1 rs1052133 polymorphism and the susceptibility to the nasopharyngeal carcinoma: a systematic review and meta-analysis2023Venue not listedstudy-registration
  21. A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).2022Journal of Clinical Oncologyconference-abstract
  22. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2022Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 2220232024: 3320242025: 112025

1 hospital in Zhuhai for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIEarly detection & endoscopyMolecular markers & genomics
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. Integrative analysis of saliva-derived exosomal proteome and lipidome for the diagnosis of esophageal squamous cell carcinoma.2025BMC cancerFree full text
  2. Deep Learning for Automatic Gross Tumor Volumes Contouring in Esophageal Cancer Based on Contrast-Enhanced Computed Tomography Images: A Multi-Institutional Study.2024International journal of radiation oncology, biology, physics
  3. In Vivo Detection of Lymph Nodes Metastasis of ESCC Using CXCR4-Targeted Tracer [64Cu]Cu-NOTA-CP01.2024Molecular imaging and biology
  4. Prospective study of 99mTc-3PRGD2 SPECT/CT diagnosing metastatic lymph nodes in esophageal squamous cell carcinoma.2024Thoracic cancerFree full text
  5. Radiomics Nomogram with Added Nodal Features Improves Treatment Response Prediction in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Study.2023Annals of surgical oncology
  6. Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes.2023European journal of nuclear medicine and molecular imaging
  7. NIR-II Navigation with an EGFR-Targeted Probe Improves Imaging Resolution and Sensitivity of Detecting Micrometastases in Esophageal Squamous Cell Carcinoma Xenograft Models.2022Molecular pharmaceutics
  8. Identification of an IGF2BP2-Targeted Peptide for Near-Infrared Imaging of Esophageal Squamous Cell Carcinoma.2022Molecules (Basel, Switzerland)Free full text
  9. Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-Met-targeted probe in a preclinical xenograft model.2021Journal of controlled release : official journal of the Controlled Release Society
  10. Preclinical Evaluation of [64Cu]NOTA-CP01 as a PET Imaging Agent for Metastatic Esophageal Squamous Cell Carcinoma.2021Molecular pharmaceutics
All its trials on ClinicalTrials.gov, any status4
  1. Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal CancerStatus unknownNCT04161560Lead sponsorPhase 1Start 2019-11
  2. Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCCStatus unknownNCT04514822Lead sponsorN/AStart 2019-03
  3. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  4. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)5
  1. LOMIA-T: A Transformer-Based LOngitudinal Medical Image Analysis Framework for Predicting Treatment Response of Esophageal Cancer2024Lecture notes in computer scienceconference-paper
  2. Single-cell transcriptomics reveals the landscape of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and the potential resistance role of LGALS12024Research Squarepreprint
  3. Identification lymph node metastasis in esophageal squamous cell carcinoma using whole slide images and a hybrid network of multiple instance and transfer learning2023Biomedical Signal Processing and Controlarticle
  4. 263 MEDIASTINAL LYMPHADENECTOMY UNDER LAPAROSCOPIC ASSISTED SINGLE-PORT INFLATABLE MEDIASTINOSCOPY THROUGH LEFT NECK APPROACH2021Diseases of the Esophagusarticle
  5. IGF2BP2 Promotes the Proliferation, Invasion and Migration of Esophageal Carcinoma Cells via Activation of the PI3K/AKT/EMT Signaling Pathway2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 43 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
43
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 7720212022: 111120222023: 7720232024: 7720242025: 10102025

2 hospitals in Zhuhai for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06060769

    Age 18 years to Not stated (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  2. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  3. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led43
  1. Fibrates Inhibit PLTP-induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. ATP6V1D drives hepatocellular carcinoma stemness and progression via both lysosome acidification-dependent and -independent mechanisms.2025AutophagyFree full text
  3. SLC35C2 promotes stemness and progression in hepatocellular carcinoma by activating lipogenesis.2025Cellular signalling
  4. Fibroblast activation protein peptide-targeted NIR-I/II fluorescence imaging for stable and functional detection of hepatocellular carcinoma.2025European journal of nuclear medicine and molecular imaging
  5. Predicting early recurrence in hepatocellular carcinoma after hepatectomy using GD-EOB-DTPA enhanced MRI-based model.2025European journal of radiology
  6. Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.2025Hepatology (Baltimore, Md.)
  7. CHAF1B: the hidden culprit behind sorafenib resistance in hepatocellular carcinoma.2025International journal of medical sciencesFree full text
  8. Polyoxometalate-based injectable coacervate inhibits HCC metastasis after incomplete radiofrequency ablation via scavenging ROS.2025Journal of nanobiotechnologyFree full text
  9. Hepatocytes and Hepatic Stellate Cells Carry Different Levels of DNA Damage due to Their Sensitivity to Oxidative Stress in Chronic Hepatitis B.2025Journal of viral hepatitis
  10. Radiomics Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma Using 3D Ultrasound and Whole-Slide Image Fusion.2025Small methods
  11. Histopathological diagnosis of microvascular invasion in hepatocellular carcinoma: Is it reliable?2025World journal of gastroenterologyFree full text
  12. TMX2 potentiates cell viability of hepatocellular carcinoma by promoting autophagy and mitophagy.2024AutophagyFree full text
  13. Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity.2024Cancer immunology research
  14. An integrative pan-cancer analysis of the molecular characteristics of dietary restriction in tumour microenvironment.2024EBioMedicineFree full text
  15. Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  16. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.2024Journal of controlled release : official journal of the Controlled Release Society
  17. Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma.2024Journal of nanobiotechnologyFree full text
  18. DNA damages in hepatocytes are amended by an inflammation-driven rescue repair mechanism in chronic hepatitis B.2024Pathology, research and practice
  19. Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma.2023ACS applied materials & interfaces
  20. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.2023BMC cancerFree full text
  21. Impact of Transarterial Chemoembolization or Hepatic Artery Infusion Chemotherapy on Liver Function after Hepatocellular Carcinoma Resection: An Observational Study.2023Digestion
  22. NIR-II fluorescence-guided liver cancer surgery by a small molecular HDAC6 targeting probe.2023EBioMedicineFree full text
  23. Mitochondrial ROS driven by NOX4 upregulation promotes hepatocellular carcinoma cell survival after incomplete radiofrequency ablation by inducing of mitophagy via Nrf2/PINK1.2023Journal of translational medicineFree full text
  24. Targeting inflammatory macrophages rebuilds therapeutic efficacy of DOT1L inhibition in hepatocellular carcinoma.2023Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  25. Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  26. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.2022Cancer biology & therapyFree full text
  27. RNA Helicase DDX24 Stabilizes LAMB1 to Promote Hepatocellular Carcinoma Progression.2022Cancer research
  28. Hsa-microRNA-370-3p targeting Snail and Twist1 suppresses IL-8/STAT3-driven hepatocellular carcinoma metastasis.2022Cancer scienceFree full text
  29. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.2022Digestive diseases and sciences
  30. Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α.2022Drug design, development and therapyFree full text
  31. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.2022European radiology
  32. Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer.2022Frontiers in endocrinologyFree full text
  33. Lu3+-based nanoprobe for virtual non-contrast CT imaging of hepatocellular carcinoma.2022Journal of controlled release : official journal of the Controlled Release Society
  34. Combined HIF-1α and SHH Up-Regulation Is a Potential Biomarker to Predict Poor Prognosis in Postoperative Hepatocellular Carcinoma.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  35. Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  36. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression.2022Journal of nanobiotechnologyFree full text
  37. Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma.2021ACS applied materials & interfaces
  38. Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells.2021Antiviral research
  39. Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC.2021Biomaterials science
  40. Ribonucleic acid-binding protein CPSF6 promotes glycolysis and suppresses apoptosis in hepatocellular carcinoma cells by inhibiting the BTG2 expression.2021Biomedical engineering onlineFree full text
  41. Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres.2021European journal of nuclear medicine and molecular imaging
  42. Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B.2021Hepatology internationalFree full text
  43. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.2021The Journal of general virology
All its trials on ClinicalTrials.gov, any status5
  1. Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance ImagingRecruitingNCT06060769Lead sponsorStart 2023-09
  2. Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular CarcinomaWithdrawnNCT03636607Lead sponsorN/AStart 2018-06
  3. HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in ChinaStatus unknownNCT02743065Lead sponsorStart 2016-09
  4. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  5. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Zhuhai for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Zhuhai for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Zhuhai for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Zhuhai for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Zhuhai for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06060782

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineRecruitingNCT06060782Lead sponsorPhase 1Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhuhai for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Chinese-language papers (not in the count)1
  1. [Prevalence Rate and Risk Factors of Hypothyroidism in Children with Beta Thalassemia Major in Zhuhai Area].2021Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Zhuhai for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Zhuhai for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes.2023Annals of clinical and translational neurology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Zhuhai for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中山大学附属第五医院

Fifth Affiliated Hospital of Sun Yat-sen University

珠海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Fifth Affiliated Hospital of Sun Yat-Sen University; Fifth Affiliated Hospital Sun Yat-sen University

Suggest a correctionDownload the data